Trevi Therapeutics (TRVI) Accumulated Depreciation & Amortization (2018 - 2025)
Trevi Therapeutics' quarterly Accumulated Depreciation & Amortization came in at $359000.0 in Q4 2025, up 57.46% year-on-year from $228000.0 in Q4 2024, and up 57.46% quarter-over-quarter from $228000.0 in Q4 2024.
Trevi Therapeutics has reported Accumulated Depreciation & Amortization for 8 years, with the latest figure at $359000.0 in Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 57.46% year-over-year to $359000.0; the trailing twelve-month figure through Dec 2025 stood at $359000.0 (up 57.46% YoY), and the FY2025 full-year result was $359000.0, up 57.46% from the prior year.
- Accumulated Depreciation & Amortization for Q4 2025 stood at $359000.0, up from $228000.0 in the prior quarter.
- The five-year high for Accumulated Depreciation & Amortization was $359000.0 in Q4 2025, with the low at $134000.0 in Q4 2023.
- Average Accumulated Depreciation & Amortization over 5 years is $225600.0, with a median of $225000.0 recorded in 2022.
- Year-over-year, Accumulated Depreciation & Amortization slumped 40.44% in 2023 and jumped 70.15% in 2024.
- Tracing TRVI's Accumulated Depreciation & Amortization over 5 years: stood at $182000.0 in 2021, then rose by 23.63% to $225000.0 in 2022, then tumbled by 40.44% to $134000.0 in 2023, then jumped by 70.15% to $228000.0 in 2024, then surged by 57.46% to $359000.0 in 2025.
- The last three Accumulated Depreciation & Amortization figures came in at $359000.0 (Q4 2025), $228000.0 (Q4 2024), and $134000.0 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 359,000.00 |
| Dec 31, 2025 | 359,000.00 |
| Dec 31, 2024 | 228,000.00 |
| Dec 31, 2024 | 228,000.00 |
| Dec 31, 2023 | 134,000.00 |
| Dec 31, 2023 | 134,000.00 |
| Dec 31, 2022 | 225,000.00 |
| Dec 31, 2022 | 225,000.00 |
| Dec 31, 2021 | 182,000.00 |
| Dec 31, 2021 | 182,000.00 |
| Dec 31, 2020 | 132,000.00 |
| Dec 31, 2020 | 132,000.00 |
| Dec 31, 2019 | 85,000.00 |
| Dec 31, 2019 | 85,000.00 |
| Dec 31, 2018 | 46,000.00 |
| Dec 31, 2018 | 46,000.00 |